Key result
Intensive therapy with /day rosuvastatin plus 1,/day eicosapentaenoic acid reduced the lipid index of native coronary plaques compared to standard therapy.
Why the study?
In-stent neoatherosclerosis carries a risk of future cardiovascular events through atherosclerotic progression in non-stented lesions.
Does intensive therapy with rosuvastatin and eicosapentaenoic acid reduce native coronary atherosclerotic progression in patients with in-stent neoatherosclerosis?
RCT (n=42)
Open-label, blind-endpoint evaluation
1:1
No
Does intensive therapy with rosuvastatin and eicosapentaenoic acid reduce native coronary atherosclerotic progression in patients with in-stent neoatherosclerosis?
Answers are grounded in this paper and cite their sources.
BACKGROUND: In-stent neoatherosclerosis (NA) is a risk for future cardiovascular events through atherosclerotic progression in non-stented lesions. Using optical coherence tomography, this study assessed the efficacy of intensive therapy with 10 mg/day rosuvastatin plus 1,800 mg/day eicosapentaenoic acid (EPA) vs. standard 2.5 mg/day rosuvastatin therapy on native coronary plaques in patients with NA. METHODS AND RESULTS: This was a subgroup analysis of the randomized LINK-IT trial, which was designed to compare changes in the lipid index in NA between intensive and standard therapy for 12 months. In all, 42 patients with native coronary plaques and NA were assessed. Compared with standard therapy, intensive therapy resulted in greater decreases in serum low-density lipoprotein cholesterol concentrations and greater increases in serum 18-hydroxyeicosapentaenoic acid concentrations, with significantly greater decreases in the lipid index and macrophage grade in both NA (-24 vs. 217 [P<0.001] and -15 vs. 24 [P<0.001], respectively) and native coronary plaques (-112 vs. 29 [P<0.001] and -17 vs. 1 [P<0.001], respectively) following intensive therapy. Although there was a greater increase in the macrophage grade in NA than in native coronary plaques in the standard therapy group, in the intensive therapy group there were comparable reductions in macrophage grade between NA and native coronary plaques. CONCLUSIONS: Compared with standard therapy, intensive therapy prevented atherosclerotic progression more effectively in native coronary plaques in patients with NA.
No takes yet. Share an insight, caveat, or question.
Sugizaki et al. (2020) conducted an RCT in In-stent neoatherosclerosis and native coronary plaques (n=42). Rosuvastatin and eicosapentaenoic acid vs. 2.5 mg/day rosuvastatin was evaluated on Change in lipid index of native coronary plaques (p=<0.001). Intensive therapy with /day rosuvastatin plus 1,/day eicosapentaenoic acid reduced the lipid index of native coronary plaques compared to standard therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: